OrthoPediatrics Corp. filings document the regulatory record of a Nasdaq-listed medical device company focused on pediatric orthopedics. Its Form 8-K reports include quarterly and annual results, unaudited financial statements, revenue trends across Trauma and Deformity, Scoliosis, Sports Medicine/Other and OrthoPediatrics Specialty Bracing, as well as management guidance and investor presentation materials furnished under Regulation FD.
The company’s filings also cover governance and ownership matters through proxy statements, including board elections, executive compensation and equity awards. Material-event filings describe financing arrangements such as amendments to credit agreements and delayed draw term loan capacity, tying capital structure disclosures to the company’s operating and liquidity needs.
OrthoPediatrics Corp director Bryan W. Hughes received a stock award of 11,436 shares of common stock. The shares were granted at no cash cost as equity compensation, rather than bought on the open market. After this award, his direct holdings total 32,663 shares.
A footnote explains that these holdings include restricted stock awards totaling 17,959 shares, which typically vest over time subject to conditions. The filing reports only this grant transaction and does not show any share sales or option exercises.
ORTHOPEDIATRICS CORP director Kelly Laine Fischer received a stock-based compensation grant. On June 9, 2026, Fischer was awarded 11,436 shares of Common Stock at $0.00 per share, reported as a grant or other acquisition rather than an open-market purchase.
Following this award, Fischer’s directly held position totals 15,781 shares, which the filing notes includes restricted stock awards. The transaction reflects routine equity compensation for a director and does not represent a discretionary market trade in the company’s shares.
Riccitelli Samuel D reported acquisition or exercise transactions in this Form 4 filing.
ORTHOPEDIATRICS CORP director Samuel D. Riccitelli received a stock grant of 11,436 shares of Common Stock. The award was granted at no cash cost per share and is held directly. Following this grant, he directly owns 31,859 shares, including restricted stock awards totaling 17,959 shares.
Ruf Harold reported acquisition or exercise transactions in this Form 4 filing.
OrthoPediatrics Corp director Harold Ruf reported a stock award of 11,436 shares of common stock. The award was granted at a price of $0.00 per share as equity compensation, not an open-market purchase.
Following the grant, Ruf directly holds 19,837 shares of common stock. The filing also reports indirect holdings of 2,400 shares through The Last Chance Legacy Trust and 19,247 shares through the Harald Ruf Roth IRA, where he is deemed to have a pecuniary interest under Section 16 regulations. Certain positions include restricted stock awards noted in the footnotes.
Bailey David R reported acquisition or exercise transactions in this Form 4 filing.
ORTHOPEDIATRICS CORP President and CEO David R. Bailey received a grant of 119,140 shares of Common Stock on June 9, 2026. The award was reported at a price of $0.00 per share, indicating a stock-based compensation grant rather than an open-market purchase.
Following this grant, Bailey directly holds 417,160 shares of the company’s Common Stock. The holdings include restricted stock awards totaling 307,031 shares, which typically vest over time and are subject to continued service or performance conditions.
OrthoPediatrics Corp director Jimmy Duane McDonald received a stock grant. On June 9, 2026, he acquired 11,436 shares of common stock as a grant or award at a stated price of $0.00 per share, bringing his direct holdings to 24,568 shares, including 17,959 restricted stock awards.
Infante (Reynolds) Marie C reported acquisition or exercise transactions in this Form 4 filing.
OrthoPediatrics Corp director Marie C. Infante received an equity grant of 11,436 shares of common stock on June 9, 2026. The shares were awarded at a price of $0.00 per share, indicating a compensation-related stock award rather than an open-market purchase.
Following this grant, Infante directly holds 31,202 shares of OrthoPediatrics common stock. A footnote explains that this total includes restricted stock awards totaling 17,959 shares, which are typically subject to vesting or service conditions.
Throdahl Mark C reported acquisition or exercise transactions in this Form 4 filing.
ORTHOPEDIATRICS CORP director Mark C. Throdahl reported a stock award and updated share holdings. He received a grant of 11,436 shares of common stock at no cost, bringing his direct ownership to 179,317 shares, which includes 38,660 restricted stock awards.
He also reported 22,497 shares held indirectly through a trust. These entries reflect compensation-related equity awards and the current size of his direct and indirect positions, rather than open‑market buying or selling.
ORTHOPEDIATRICS CORP director George Sinclair Mitchell Dyer received an equity grant of 11,436 shares of Common Stock on June 9, 2026. The shares were acquired at no stated purchase price as a grant or award and increased his direct holdings to 24,568 shares. A footnote states that this total includes restricted stock awards of 17,959 shares, indicating a significant portion of his position is subject to vesting or other restrictions as part of his compensation.
OrthoPediatrics Corp. reported the results of its 2026 Annual Meeting of Stockholders held on June 4, 2026. Stockholders elected four directors – George S. M. Dyer, Kelly Fischer, David R. Pelizzon, and Harald Ruf – for terms running until the 2029 annual meeting.
Stockholders approved, on an advisory basis, the compensation of the company’s named executive officers with 15,953,457 votes for, 2,859,793 against, and 39,764 abstentions, plus 1,827,535 broker non-votes. They also approved an amendment to the 2024 Incentive Award Plan to add 2,050,000 shares, bringing the total shares authorized under the plan to 3,679,000.
In addition, stockholders approved the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 20,479,183 votes for, 154,131 against, and 47,235 abstentions.